PTC Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

EarningsSephiencePositive

AI Analysis

Summary

PTC Therapeutics reported Q2 2026 total revenue of $361 million and raised full-year 2026 guidance to $1.18-$1.28 billion total revenue with product revenue expected between $850-$950 million. The company highlighted robust performance driven by Sephience and other product sales.

Financial Highlights

Revenue

$361 million Q2 2026 total revenue ($239 million product revenue)

Guidance

Full-year 2026 expected total revenue $1.18 to $1.28 billion; full-year product revenue guidance $850 to $950 million

Importance:4/10

Sentiment:

0.60

earningsfinancial_guidancerevenue_beatguidance_raise

Related Companies

$PTCT

Read the original article

Published by PR Newswire Biotech on July 30, 2026 8:01 PM

Read Original